520 related articles for article (PubMed ID: 26954316)
1. Anti-IL-17 Agents for Psoriasis: A Review of Phase III Data.
Farahnik B; Beroukhim K; Nakamura M; Abrouk M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J
J Drugs Dermatol; 2016 Mar; 15(3):311-6. PubMed ID: 26954316
[TBL] [Abstract][Full Text] [Related]
2. Anti-IL-17 phase II data for psoriasis: A review.
Brown G; Malakouti M; Wang E; Koo JY; Levin E
J Dermatolog Treat; 2015 Feb; 26(1):32-6. PubMed ID: 24552447
[TBL] [Abstract][Full Text] [Related]
3. Review of IL-17 inhibitors for psoriasis.
Amin M; Darji K; No DJ; Bhutani T; Wu JJ
J Dermatolog Treat; 2018 Jun; 29(4):347-352. PubMed ID: 29058501
[No Abstract] [Full Text] [Related]
4. Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature.
Abrouk M; Gandy J; Nakamura M; Lee K; Brodsky M; Singh R; Zhu H; Farahnik B; Bhutani T; Koo J
Skin Therapy Lett; 2017 Jul; 22(4):1-6. PubMed ID: 28732152
[TBL] [Abstract][Full Text] [Related]
5. Anti-interleukin-17 treatment of psoriasis.
Jinna S; Strober B
J Dermatolog Treat; 2016 Aug; 27(4):311-5. PubMed ID: 26943806
[TBL] [Abstract][Full Text] [Related]
6. Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
Canavan TN; Elmets CA; Cantrell WL; Evans JM; Elewski BE
Am J Clin Dermatol; 2016 Feb; 17(1):33-47. PubMed ID: 26649440
[TBL] [Abstract][Full Text] [Related]
7. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
[TBL] [Abstract][Full Text] [Related]
9. Anti-IL-23 Phase II Data for Psoriasis: A Review.
Beroukhim K; Danesh MJ; Nguyen C; Austin A; Koo J; Levin E
J Drugs Dermatol; 2015 Oct; 14(10):1093-6. PubMed ID: 26461819
[TBL] [Abstract][Full Text] [Related]
10. Anti-IL17 therapies for psoriasis.
Silfvast-Kaiser A; Paek SY; Menter A
Expert Opin Biol Ther; 2019 Jan; 19(1):45-54. PubMed ID: 30500317
[TBL] [Abstract][Full Text] [Related]
11. IL-17 inhibitors for psoriasis.
Paek SY; Frieder J; Kivelevitch D; Menter MA
Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
[TBL] [Abstract][Full Text] [Related]
12. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
Puig L
Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
[TBL] [Abstract][Full Text] [Related]
13. Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis.
Amin M; Darji K; No DJ; Wu JJ
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1627-1632. PubMed ID: 28667777
[TBL] [Abstract][Full Text] [Related]
14. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
Leonardi C; Matheson R; Zachariae C; Cameron G; Li L; Edson-Heredia E; Braun D; Banerjee S
N Engl J Med; 2012 Mar; 366(13):1190-9. PubMed ID: 22455413
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
Chiricozzi A
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():9-20. PubMed ID: 25398488
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab (AIN457) for the treatment of psoriasis.
López-Ferrer A; Vilarrasa E; Puig L
Expert Rev Clin Immunol; 2015; 11(11):1177-88. PubMed ID: 26428036
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis.
Chen Y; Qian T; Zhang D; Yan H; Hao F
Immunotherapy; 2015; 7(9):1023-37. PubMed ID: 26055639
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
[TBL] [Abstract][Full Text] [Related]
19. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
20. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
